Learning Objectives
Dr. Anna Tinker is a Medical Oncologist at the British Columbia Cancer, Vancouver Centre and a Clinical Associate Professor in the Department of Medicine at the University of British Columbia. Her clinical expertise is in the treatment of women with gynecologic cancers. She is presently the Chair of the Provincial Gyne Oncology Tumour Group. She is an active member of the Canadian Cancer Trials Group, participating as study chair, Co-Lead of the Ovarian Cancer Working Group Committee and she serves on the Gynecologic Cancers Steering Committee – Ovarian Task Force for the National Cancer Institute (US). She is presently co-leading the GOC Immunotherapy CoP with Dr. Liat Hogen.
Dr. Hogen is a Gynecologic Oncologist at UHN and Mount Sinai Health System. She completed her Gyn Onc fellowship in 2017, at the University of Toronto. She is an assistant professor at the OBGYN department, University of Toronto. Her research and clinical interest rare subtypes of epithelial ovarian cancer tumour, debulking procedures, minimally invasive surgeries for gynecological malignancies, surgical management, and innovation for epithelial ovarian cancer, developing a multidisciplinary model for evaluation and treatment of ovarian cancer patients.
WHO WE ARE Fueled by our human health care mission, we’re an inspired team of innovators relentlessly pursuing ways to improve the lives of patients and their families. WHAT IS human health care? It's our way of life at Eisai — giving our first thought to patients and their families. Doing so drives us to create breakthrough solutions and medicines for them. HOW WE BRING human health care TO LIFE Breakthrough medicines are just the beginning. human health care sparks a multitude of ways in which we improve the lives of patients, their families and caregivers. IT’S ONE THING TO TALK ABOUT PUTTING PATIENTS FIRST. IT’S QUITE ANOTHER TO DO IT FOR MORE THAN THREE DECADES. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. In 2011, Eisai Canada joined in pursuing this goal. We’ve been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve. PRODUCTS How does human health care lead to breakthrough products? The key is understanding the true needs of patients. We know in our hearts how the possibility of a breakthrough can help patients and their families keep fighting. That's why we keep fighting to discover and develop solutions. Banzel® Dayvigo™ Lenvima® Halaven® Fycompa® For more information, please visit our website at www.eisai.ca
To make a difference in the lives of people through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
